Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.
Epithalon (Epitalon, AEDG): Research Overview
Last reviewed: September 16, 2026
Epithalon, also written Epitalon or Epithalone, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG) [1]. According to a 2025 review in International Journal of Molecular Sciences, the peptide was designed on the basis of the amino acid composition of Epithalamin, a bovine pineal gland extract, and was subsequently identified within a pineal gland polypeptide complex solution [1]. That review frames the compound as a pineal-derived peptide that has accumulated a substantial preclinical literature over approximately the last 25 years [1].
The review reports that Epithalon has been studied using in vitro, in vivo (animal), and in silico methods, and that no equivalent body of controlled human outcome data is presented as the basis for the summarised mechanisms [1]. The authors characterise the aggregate findings as indicating geroprotective and neuroendocrine effects in these experimental models, which they attribute to antioxidant, neuroprotective, and antimutagenic activities arising from both specific and nonspecific mechanisms [1]. Researchers reading this literature should note that these are model-system descriptors used by the reviewers, not clinical endpoints [1].
Several candidate mechanisms are catalogued in the review. It states that Epithalon has been reported to exert a direct influence on melatonin synthesis, to alter mRNA levels of interleukin-2, and to modulate the mitogenic activity of murine thymocytes — the last of these being an animal-derived cell model [1]. The review also reports enhanced activity of several enzymes in experimental work, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and telomerase [1]. The authors explicitly note that it remains uncertain whether these constitute the sole mechanisms of action of the compound, which places the mechanistic picture in the category of open questions rather than settled pharmacology [1].
A further limitation identified in the review is asymmetry within the literature itself. The authors observe that, despite a considerable volume of research on the biological and pharmacodynamic characteristics of Epithalon, the number of physico-chemical and structural investigations of the peptide remains quite limited [1]. The stated aim of the review is to consolidate the most important findings from the available studies and thereby describe the current state of knowledge, which makes it a secondary source summarising primary in vitro, animal, and computational work rather than a report of new experimental results [1]. Investigators designing new studies on AEDG may therefore find the structural and physico-chemical characterisation gap to be the most clearly documented deficit in the existing record [1].
In plain terms
Epithalon (also spelled Epitalon) is a short four-amino-acid peptide, Ala-Glu-Asp-Gly, that chemists built based on what was found in a pineal gland extract from cattle; it was later also found in a pineal peptide mixture [1]. A 2025 review article collected together about 25 years of research on it [1].
That research was done in cells, in animals, and in computer models — the review does not present human outcome trials as the source of the mechanisms it describes [1]. The reviewers group the reported activity under headings such as antioxidant, nerve-cell-protective, and anti-mutation effects, and they list specific observations: effects on melatonin production, changes in the messenger RNA for a signalling molecule called interleukin-2, changes in how mouse immune cells (thymocytes) divide, and increased activity of several enzymes including AChE, BuChE, and telomerase [1]. The authors are clear that they do not know whether these are the only ways the peptide acts [1].
The review also points out an imbalance in the literature: a lot has been published about what the peptide does biologically, but relatively little about its basic chemistry and molecular structure [1]. Because this is a review rather than a new experiment, it is a summary of earlier cell, animal, and computational studies, and that structural gap is the clearest unfinished area it identifies for future research [1].
Related products
References
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.. Int J Mol Sci. 2025. (in vitro) PubMed